Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20190522043672N2
IRCT20190522043672N2RecruitingPhase 2

Preventive effect of pentoxifylline in Acute Respiratory Distress Syndrome susceptible children

Mashhad University of Medical Sciences0 sites40 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
40
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
1 month to 18 years (—)
Sex
All

Inclusion Criteria

  • •All patients at risk for ARDS who have lips=4 based on lung injury prediction score (lips) and do not complete the ARDS diagnosis criteria

Exclusion Criteria

  • •Acute prenatal hypoxemia such as premature infant-related lung disease, prenatal lung injury (such as Meconium Aspiration Syndrome, pneumonia, and sepsis occurring during childbirth) are excluded.
  • •A disease that inevitably leads to death and is contrary to life
  • •Children with adrenal insufficiency
  • •Inflammation of blood vessels
  • •Patients with intolerance to methylxanthine and pentoxifylline

Investigators

Similar Trials

Completed
Phase 2
Effect of pentoxifylline in preventing contrast-induced nephropathyST elevation myocardial infarction.Acute myocardial infarction
IRCT2014092819316N1Vice chancellor for research of Mashhad University of Medical Sciences182
Recruiting
Phase 3
evaluation effect of Pentoxifylline in sepsis.neonatal late sepsis.Other sepsis
IRCT20180404039187N7Tabriz University of Medical Sciences40
Not yet recruiting
Phase 3
Investigation of the effect of pentoxifylline on Covid-19COVID _19.Multisystem inflammatory syndrome associated with COVID_19U10.9
IRCT20170609034406N8Tabriz University of Medical Sciences100
Completed
Not Applicable
Pentoxifylline and Contrast Induced NephropathyContrast Induced Nephropathy.Acute renal failure (includes acute renal impairment)
IRCT201011135161N1Vice-chancellor for Research Affairs, Shiraz University of Medical Sciences199
Active, not recruiting
Phase 1
Preventive effect of drugs on radiation damage to the liver.Irradiation damage to the liver after HDR-brachytherapy of liver metastases.
EUCTR2008-002985-70-DEniversity of Magdeburg36